ÂÜÀòÂÒÂ×

Amer Zeidan, MBBS, MHS, is an Associate Professor of Medicine (Hematology). Dr. Zeidan completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. He received his MBBS degree from the Faculty of Medicine, University of Jordan, Amman, Jordan before completing his internal medicine residency at Rochester General Hospital, Rochester, NY. Dr. Zeidan specializes in the management of MDS and acute myeloid leukemia (AML). He is a nationally and internationally recognized expert in the clinical management of myeloid malignancies. Dr. Zeidan is the principal investigator on several investigator-initiated, cooperative group, and industry sponsored clinical trials in MDS, AML, and other hematologic malignancies. Dr. Zeidan focuses on the use of immunotherapy, especially combination-based approaches for myeloid malignancies.

Dr. Zeidan is the national study chair of two multi-center trials in the NCI’s Experimental Therapeutics Clinical Trials Network (ETCTN) and the Eastern Cooperative Oncology Group (ECOG) evaluating the addition of the anti-PD-1 antibody, pembrolizumab to standard therapies in MDS and chronic myeloid leukemia. He is the principal investigator (PI) of multiple investigator-initiated trials in AML and MDS. In addition to these investigator-initiated trials within the NCI networks and in collaboration with industry, Dr. Zeidan is the local Yale PI for multiple NCI-sponsored and several phase I/II/III industry-sponsored clinical trials in myeloid malignancies in which he was heavily involved in the design of and led accrual nationally in several trials. Dr. Zeidan is also chairing the steering committee for a large pharma-sponsored randomized trial of MDS. Dr. Zeidan is currently Vice Chair of the Data Safety Monitoring Committee at Yale Cancer Center.